Furthermore, given the potential benefit of targeting the SAC as a novel approach in anticancer therapy, the BUB1 and BUBR1 structures should be important in structure-guided drug design and the development of animal models that harbor cancer-derived mutations. This evidence concerns the gene ADCY10 and cancer.